The University of Chicago Header Logo

Thomas F. Gajewski

TitleProfessor
InstitutionUniversity of Chicago
DepartmentPathology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mathias K, Rouhani S, Olson D, Bass AR, Gajewski TF, Reid P, Mathias K, Rouhani S, Olson D, Bass AR, Gajewski TF, Reid P. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 Jan 03. PMID: 36595378.
      Citations:    Fields:    
    2. MacDonald ME, Weathered RK, Stewart EC, Magold AI, Mukherjee A, Gurbuxani S, Smith H, McMullen P, Mueller J, Husain AN, Salles CM, Briquez PS, Rouhani SJ, Yu J, Trujillo J, Pyzer AR, Gajewski TF, Sperling AI, Kilarski WW, Swartz MA, MacDonald ME, Weathered RK, Stewart EC, Magold AI, Mukherjee A, Gurbuxani S, Smith H, McMullen P, Mueller J, Husain AN, Salles CM, Briquez PS, Rouhani SJ, Yu J, Trujillo J, Pyzer AR, Gajewski TF, Sperling AI, Kilarski WW, Swartz MA. Lymphatic coagulation and neutrophil extracellular traps in?lung-draining lymph nodes of COVID-19 decedents. Blood Adv. 2022 12 27; 6(24):6249-6262. PMID: 35977099; PMCID: PMC9394105.
      Citations:    Fields:    Translation:AnimalsCells
    3. Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, Chang P, Murgu S, Husain AN, Cody B, Vokes EE, Bestvina CM, Patel JD, Diehn M, Gajewski TF, Weichselbaum RR, Chmura SJ, Pitroda SP, Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, Chang P, Murgu S, Husain AN, Cody B, Vokes EE, Bestvina CM, Patel JD, Diehn M, Gajewski TF, Weichselbaum RR, Chmura SJ, Pitroda SP. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512. PMID: 36443406.
      Citations: 3     Translation:HumansCTClinical Trials
    4. Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J, Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precis Oncol. 2022 11; 6:e2200454. PMID: 36446042.
      Citations: 1     Fields:    Translation:Humans
    5. Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, Stamper CT, Changrob S, Sperling AI, Wilson PC, Gajewski TF, Hubbell JA, Swartz MA, Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, Stamper CT, Changrob S, Sperling AI, Wilson PC, Gajewski TF, Hubbell JA, Swartz MA. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci Adv. 2022 10 07; 8(40):eabn3777. PMID: 36206332; PMCID: PMC9544317.
      Citations: 8     Fields:    Translation:HumansCells
    6. Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF, Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF. Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines. Cancer Immunol Res. 2022 10 04; 10(10):1167-1174. PMID: 35977003; PMCID: PMC9530647.
      Citations:    Fields:    Translation:HumansCells
    7. Ascierto PA, Agarwala SS, Blank C, Carac? C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krogsgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfeld B, Zitvogel L, Puzanov I, Thurin M, Ascierto PA, Agarwala SS, Blank C, Carac? C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krogsgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfeld B, Zitvogel L, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). J Transl Med. 2022 09 04; 20(1):391. PMID: 36058945; PMCID: PMC9440864.
      Citations:    Fields:    Translation:HumansPHPublic Health
    8. Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H, Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 Jan 20; 41(3):528-540. PMID: 35998300; PMCID: PMC9870217.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    9. Reschke R, Gajewski TF, Reschke R, Gajewski TF. CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol. 2022 07 22; 7(73):eabq6509. PMID: 35867802.
      Citations: 7     Fields:    Translation:Cells
    10. Higgs EF, Flood BA, Pyzer AR, Rouhani SJ, Trujillo JA, Gajewski TF, Higgs EF, Flood BA, Pyzer AR, Rouhani SJ, Trujillo JA, Gajewski TF. Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools. Biopreserv Biobank. 2022 Jun 30. PMID: 35771982.
      Citations:    Fields:    
    11. Higgs EF, Bao R, Hatogai K, Gajewski TF, Higgs EF, Bao R, Hatogai K, Gajewski TF. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. J Immunother Cancer. 2022 06; 10(6). PMID: 35705315; PMCID: PMC9204399.
      Citations: 1     Fields:    Translation:HumansCells
    12. Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF, Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6). PMID: 35732350; PMCID: PMC9226983.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    13. Matson V, Gajewski TF, Matson V, Gajewski TF. Dietary modulation of the gut microbiome as an immunoregulatory intervention. Cancer Cell. 2022 03 14; 40(3):246-248. PMID: 35290783.
      Citations: 2     Fields:    Translation:Humans
    14. Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. ASO Visual Abstract: Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage 3 Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(Suppl 3):576. PMID: 34355335.
      Citations:    
    15. Gajewski T, Rouhani S, Trujillo J, Pyzer A, Yu J, Fessler J, Cabanov A, Higgs E, Cron K, Zha Y, Lu Y, Bloodworth J, Abasiyanik M, Okrah S, Flood B, Hatogai K, Leung M, Pezeshk A, Kozloff L, Reschke R, Strohbehn G, Chervin CS, Kumar M, Schrantz S, Madariaga ML, Beavis K, Yeo KT, Sweis R, Segal J, Tay S, Izumchenko E, Mueller J, Chen L, Gajewski T, Rouhani S, Trujillo J, Pyzer A, Yu J, Fessler J, Cabanov A, Higgs E, Cron K, Zha Y, Lu Y, Bloodworth J, Abasiyanik M, Okrah S, Flood B, Hatogai K, Leung M, Pezeshk A, Kozloff L, Reschke R, Strohbehn G, Chervin CS, Kumar M, Schrantz S, Madariaga ML, Beavis K, Yeo KT, Sweis R, Segal J, Tay S, Izumchenko E, Mueller J, Chen L. Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction. Res Sq. 2021 Nov 24. PMID: 34845442; PMCID: PMC8629200.
      Citations: 1     
    16. Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, Stamper CT, Changrob S, Sperling AI, Wilson PC, Gajewski TF, Hubbell JA, Swartz MA, Briquez PS, Rouhani SJ, Yu J, Pyzer AR, Trujillo J, Dugan HL, Stamper CT, Changrob S, Sperling AI, Wilson PC, Gajewski TF, Hubbell JA, Swartz MA. SARS-CoV-2 infection induces cross-reactive autoantibodies against angiotensin II. medRxiv. 2021 Nov 02. PMID: 34751272; PMCID: PMC8575143.
      Citations:    
    17. Reschke R, Yu J, Flood B, Higgs EF, Hatogai K, Gajewski TF, Reschke R, Yu J, Flood B, Higgs EF, Hatogai K, Gajewski TF. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J Immunother Cancer. 2021 09; 9(9). PMID: 34593622; PMCID: PMC8487215.
      Citations: 10     Fields:    Translation:Humans
    18. Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV, Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7). PMID: 34272305; PMCID: PMC8287618.
      Citations: 8     Fields:    Translation:Humans
    19. Gajewski TF. Frank W. Fitch (1929-2021). Nat Immunol. 2021 Jul; 22(7):799. PMID: 34099920.
      Citations:    
    20. Ascierto PA, Blank C, Dummer R, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Kalinski P, Krogsgaard M, Lo RS, Luke JJ, Neyns B, Postow MA, Quezada SA, Teng MWL, Trinchieri G, Testori A, Carac? C, Osman I, Puzanov I, Thurin M, Ascierto PA, Blank C, Dummer R, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Kalinski P, Krogsgaard M, Lo RS, Luke JJ, Neyns B, Postow MA, Quezada SA, Teng MWL, Trinchieri G, Testori A, Carac? C, Osman I, Puzanov I, Thurin M. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy). J Transl Med. 2021 06 30; 19(1):278. PMID: 34193182; PMCID: PMC8243582.
      Citations:    Fields:    Translation:Humans
    21. Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK, Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047. PMID: 34129153.
      Citations: 1     Fields:    Translation:Humans
    22. Abasiyanik MF, Flood B, Lin J, Ozcan S, Rouhani SJ, Pyzer A, Trujillo J, Zhen C, Wu P, Jumic S, Wang A, Gajewski TF, Wang P, Hartley M, Ameti B, Niemiec R, Fernando M, Mishra V, Savage P, Aydogan B, Bethel C, Matushek S, Beavis KG, Agrawal N, Segal J, Tay S, Izumchenko E, Abasiyanik MF, Flood B, Lin J, Ozcan S, Rouhani SJ, Pyzer A, Trujillo J, Zhen C, Wu P, Jumic S, Wang A, Gajewski TF, Wang P, Hartley M, Ameti B, Niemiec R, Fernando M, Mishra V, Savage P, Aydogan B, Bethel C, Matushek S, Beavis KG, Agrawal N, Segal J, Tay S, Izumchenko E. Sensitive detection and quantification of SARS-CoV-2 in saliva. Sci Rep. 2021 06 14; 11(1):12425. PMID: 34127708; PMCID: PMC8203799.
      Citations: 16     Fields:    Translation:HumansCells
    23. Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ, Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655. PMID: 33945288; PMCID: PMC8376314.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    24. Vining CC, Hsu PJ, Miller A, Olson DJ, Gajewski TF, Pytel P, Bauer BS, Millis MJ, Roggin KK, Vining CC, Hsu PJ, Miller A, Olson DJ, Gajewski TF, Pytel P, Bauer BS, Millis MJ, Roggin KK. Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma. Melanoma Res. 2021 02 01; 31(1):92-97. PMID: 33323721; PMCID: PMC7755705.
      Citations: 2     Fields:    Translation:Humans
    25. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD, Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696. PMID: 33210302; PMCID: PMC7753375.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    26. Abasiyanik MF, Flood B, Lin J, Ozcan S, Rouhani SJ, Pyzer A, Trujillo J, Zhen C, Wu P, Jumic S, Wang A, Gajewski TF, Wang P, Hartley M, Ameti B, Niemiec R, Fernando M, Aydogan B, Bethel C, Matushek S, Beavis KG, Agrawal N, Segal J, Tay S, Izumchenko E, Abasiyanik MF, Flood B, Lin J, Ozcan S, Rouhani SJ, Pyzer A, Trujillo J, Zhen C, Wu P, Jumic S, Wang A, Gajewski TF, Wang P, Hartley M, Ameti B, Niemiec R, Fernando M, Aydogan B, Bethel C, Matushek S, Beavis KG, Agrawal N, Segal J, Tay S, Izumchenko E. Sensitive detection and quantification of SARS-CoV-2 in saliva. medRxiv. 2020 Dec 07. PMID: 33330880; PMCID: PMC7743089.
      Citations: 9     
    27. Matson V, Chervin CS, Gajewski TF, Matson V, Chervin CS, Gajewski TF. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2021 01; 160(2):600-613. PMID: 33253684; PMCID: PMC8409239.
      Citations: 67     Fields:    Translation:HumansAnimals
    28. Soto Chervin C, Gajewski TF, Soto Chervin C, Gajewski TF. Microbiome-based interventions: therapeutic strategies in cancer immunotherapy. Immunooncol Technol. 2020 Dec; 8:12-20. PMID: 35757563; PMCID: PMC9216398.
      Citations: 2     
    29. Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444. PMID: 33028595; PMCID: PMC8561652.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    30. Koss B, Shields BD, Taylor EM, Storey AJ, Byrum SD, Gies AJ, Washam CL, Choudhury SR, Hyun Ahn J, Uryu H, Williams JB, Krager KJ, Chiang TC, Mackintosh SG, Edmondson RD, Aykin-Burns N, Gajewski TF, Wang GG, Tackett AJ, Koss B, Shields BD, Taylor EM, Storey AJ, Byrum SD, Gies AJ, Washam CL, Choudhury SR, Hyun Ahn J, Uryu H, Williams JB, Krager KJ, Chiang TC, Mackintosh SG, Edmondson RD, Aykin-Burns N, Gajewski TF, Wang GG, Tackett AJ. Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719. PMID: 33004350; PMCID: PMC7642172.
      Citations: 7     Fields:    Translation:AnimalsCells
    31. Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Carac? C, Thurin M, Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Carac? C, Thurin M. Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). J Transl Med. 2020 09 07; 18(1):346. PMID: 32894202; PMCID: PMC7487701.
      Citations: 1     Fields:    Translation:Humans
    32. Gajewski TF, Higgs EF, Gajewski TF, Higgs EF. Immunotherapy with a sting. Science. 2020 08 21; 369(6506):921-922. PMID: 32820113.
      Citations: 14     Fields:    Translation:Humans
    33. Gajewski TF, Cron KR, Gajewski TF, Cron KR. cDC1 dysregulation in cancer: An opportunity for intervention. J Exp Med. 2020 08 03; 217(8). PMID: 32697286; PMCID: PMC7398176.
      Citations: 2     Fields:    Translation:HumansCells
    34. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol A, Weiss A, Danahey K, Karrison TG, Edens CC, Ventura IB, Pettit NN, Patel B, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD, Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol A, Weiss A, Danahey K, Karrison TG, Edens CC, Ventura IB, Pettit NN, Patel B, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. medRxiv. 2020 Jul 26. PMID: 32743594; PMCID: PMC7386518.
      Citations:    
    35. Gajewski TF, Gajewski TF. Strategies to overcome resistance to PD-1 inhibitors. Clin Adv Hematol Oncol. 2020 May; 18(5):270-272. PMID: 32628654.
      Citations:    Fields:    Translation:Humans
    36. Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS, Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1). PMID: 32300051; PMCID: PMC7204613.
      Citations: 40     Fields:    Translation:HumansCellsPHPublic Health
    37. Olson DJ, Rajagopal P, Tjota MY, Venkataraman G, Luke JJ, Gajewski TF, Olson DJ, Rajagopal P, Tjota MY, Venkataraman G, Luke JJ, Gajewski TF. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. J Immunother Cancer. 2020 03; 8(1). PMID: 32169870; PMCID: PMC7069276.
      Citations: 3     Fields:    Translation:Humans
    38. Williams JB, Li S, Higgs EF, Cabanov A, Wang X, Huang H, Gajewski TF, Williams JB, Li S, Higgs EF, Cabanov A, Wang X, Huang H, Gajewski TF. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602. PMID: 32001684; PMCID: PMC6992737.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    39. Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jim?nez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R, Jenkner A, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G, Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jim?nez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R, Jenkner A, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer. 2020 03; 127:52-66. PMID: 31986450.
      Citations: 19     Fields:    Translation:Humans
    40. Gajewski TF, Fessler J, Gajewski TF, Fessler J. PAK4 as a cancer immune-evasion target. Nat Cancer. 2020 01; 1(1):18-19. PMID: 35121838.
      Citations: 3     Translation:Humans
    41. Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 Apr; 30(4):589-596. PMID: 31987276.
      Citations:    
    42. Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA, Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53. PMID: 31732523; PMCID: PMC6942621.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    43. Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, Matijevich K, Gajewski TF, Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, Matijevich K, Gajewski TF. Secondary resistance to immunotherapy associated with ?-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295. PMID: 31703593; PMCID: PMC6839232.
      Citations: 52     Fields:    Translation:HumansCells
    44. Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Carac? C, Thurin M, Puzanov I, Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Carac? C, Thurin M, Puzanov I. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). J Transl Med. 2019 07 22; 17(1):234. PMID: 31331337; PMCID: PMC6647284.
      Citations: 6     Fields:    Translation:HumansCells
    45. Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF, Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. STING pathway agonism as a cancer therapeutic. Immunol Rev. 2019 07; 290(1):24-38. PMID: 31355488; PMCID: PMC6814203.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    46. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC, Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019 08; 20(8):1083-1097. PMID: 31221619.
      Citations: 294     Fields:    Translation:HumansCTClinical Trials
    47. Fessler J, Matson V, Gajewski TF, Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019 04 17; 7(1):108. PMID: 30995949; PMCID: PMC6471869.
      Citations: 104     Fields:    Translation:HumansAnimals
    48. Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM, Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 04 01; 30(4):589-596. PMID: 30689736; PMCID: PMC6503625.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    49. Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS, Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019 03 20; 7(1):80. PMID: 30894212; PMCID: PMC6425606.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    50. Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH, Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin Cancer Res. 2019 07 15; 25(14):4202-4210. PMID: 30804019; PMCID: PMC6635001.
      Citations: 108     Fields:    Translation:HumansAnimalsCells
    51. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF, Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/?-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083. PMID: 30635339; PMCID: PMC6522301.
      Citations: 245     Fields:    Translation:HumansCells
    52. Blaha DT, Anderson SD, Yoakum DM, Hager MV, Zha Y, Gajewski TF, Kranz DM, Blaha DT, Anderson SD, Yoakum DM, Hager MV, Zha Y, Gajewski TF, Kranz DM. High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions. Cancer Immunol Res. 2019 01; 7(1):50-61. PMID: 30425106; PMCID: PMC6324732.
      Citations: 13     Fields:    
    53. Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF, Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF. Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018 Nov 10; 36(32):3223-3230. PMID: 30265610; PMCID: PMC6225502.
      Citations: 144     Fields:    
    54. Miller ML, McIntosh CM, Williams JB, Wang Y, Hollinger MK, Isaad NJ, Moon JJ, Gajewski TF, Chong AS, Alegre ML, Miller ML, McIntosh CM, Williams JB, Wang Y, Hollinger MK, Isaad NJ, Moon JJ, Gajewski TF, Chong AS, Alegre ML. Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance. Cell Rep. 2018 08 21; 24(8):2112-2126. PMID: 30134172; PMCID: PMC6142813.
      Citations: 13     Fields:    Translation:HumansAnimals
    55. Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA, Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 11; 17(11):2399-2411. PMID: 30097487.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    56. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV, Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2018 08 09; 174(4):1031-1032. PMID: 30096300.
      Citations: 69     Fields:    
    57. Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Carac? C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M, Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Carac? C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J Transl Med. 2018 07 21; 16(1):207. PMID: 30031393; PMCID: PMC6054754.
      Citations: 3     Fields:    Translation:Humans
    58. Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF, Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018 07 16; 6(1):73. PMID: 30012206; PMCID: PMC6048909.
      Citations: 24     Fields:    Translation:Humans
    59. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR, Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317. PMID: 29948021; PMCID: PMC6739841.
      Citations: 7     Fields:    Translation:HumansCells
    60. Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL, Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44. PMID: 29848375; PMCID: PMC5977556.
      Citations: 26     Fields:    Translation:Humans
    61. Gajewski TF, Gajewski TF. Fast Forward - Neoadjuvant Cancer Immunotherapy. N Engl J Med. 2018 05 24; 378(21):2034-2035. PMID: 29791816.
      Citations: 4     Fields:    Translation:Humans
    62. Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R, Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24. PMID: 29618376; PMCID: PMC5883337.
      Citations: 6     Fields:    Translation:HumansCells
    63. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF, Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018 03 23; 359(6382):1366-1370. PMID: 29567708.
      Citations: 244     Fields:    Translation:Humans
    64. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ, Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618. PMID: 29437535; PMCID: PMC5978468.
      Citations: 211     Fields:    Translation:HumansCTClinical Trials
    65. Horton BL, Gajewski TF, Horton BL, Gajewski TF. Back from the dead: TIL apoptosis in cancer immune evasion. Br J Cancer. 2018 02 06; 118(3):309-311. PMID: 29360810; PMCID: PMC5808044.
      Citations: 3     Fields:    Translation:HumansCells
    66. Spranger S, Gajewski TF, Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018 03; 18(3):139-147. PMID: 29326431; PMCID: PMC6685071.
      Citations: 266     Fields:    Translation:HumansCells
    67. Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W, Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W. WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol. 2018; 7:1. PMID: 29344432; PMCID: PMC5765712.
      Citations: 9     
    68. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF, Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 01 05; 359(6371):104-108. PMID: 29302014; PMCID: PMC6707353.
      Citations: 978     Fields:    Translation:HumansAnimalsCells
    69. Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF, Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF. Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018 01; 6(1):14-24. PMID: 29097422; PMCID: PMC5754226.
      Citations: 76     Fields:    Translation:HumansAnimalsCells
    70. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Mart?n-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA, Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Mart?n-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16. PMID: 29033130; PMCID: PMC5685550.
      Citations: 780     Fields:    Translation:HumansCells
    71. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV, Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10. PMID: 28886381; PMCID: PMC8034392.
      Citations: 580     Fields:    Translation:HumansCellsCTClinical Trials
    72. Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM, Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350. PMID: 28489678.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    73. Spranger S, Dai D, Horton B, Gajewski TF, Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017 05 08; 31(5):711-723.e4. PMID: 28486109; PMCID: PMC5650691.
      Citations: 533     Fields:    Translation:AnimalsCells
    74. Fessler JL, Gajewski TF, Fessler JL, Gajewski TF. The Microbiota: A New Variable Impacting Cancer Treatment Outcomes. Clin Cancer Res. 2017 07 01; 23(13):3229-3231. PMID: 28446507; PMCID: PMC5627769.
      Citations: 11     Fields:    Translation:Humans
    75. Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF, Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017 02; 214(2):381-400. PMID: 28115575; PMCID: PMC5294847.
      Citations: 73     Fields:    Translation:AnimalsCells
    76. Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF, Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017 07 01; 23(13):3269-3276. PMID: 28053021; PMCID: PMC5496788.
      Citations: 126     Fields:    Translation:HumansCTClinical Trials
    77. Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S, Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Adv Exp Med Biol. 2017; 1036:19-31. PMID: 29275462; PMCID: PMC6693322.
      Citations: 126     Fields:    Translation:HumansAnimalsCells
    78. Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Catal? I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, Garc?a N, Perkins AS, Bonifaci N, Skowron M, G?mez-Bald? L, Hern?ndez V, Mart?nez-Aranda A, Mart?nez-Iniesta M, Serrat X, Cer?n J, Brunet J, Barretina MP, Gil M, Falo C, Fern?ndez A, Morilla I, Pernas S, Pl? MJ, Andreu X, Segu? MA, Ballester R, Castell? E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, S?nchez-Mut JV, S?nchez-C?spedes M, Cordero A, G?mez-Miragaya J, Palomero L, G?mez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, L?pez-Bigas N, Vald?s-Mas R, Puente XS, Vi?als F, Casanovas O, Graupera M, Hern?ndez-Losa J, Ram?n Y Cajal S, Garc?a-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Mart?n-Mart?n N, Matheu A, Carracedo A, Gonz?lez-Su?rez E, Nanjundan M, Cort?s J, L?zaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA, Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Catal? I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, Garc?a N, Perkins AS, Bonifaci N, Skowron M, G?mez-Bald? L, Hern?ndez V, Mart?nez-Aranda A, Mart?nez-Iniesta M, Serrat X, Cer?n J, Brunet J, Barretina MP, Gil M, Falo C, Fern?ndez A, Morilla I, Pernas S, Pl? MJ, Andreu X, Segu? MA, Ballester R, Castell? E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, S?nchez-Mut JV, S?nchez-C?spedes M, Cordero A, G?mez-Miragaya J, Palomero L, G?mez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, L?pez-Bigas N, Vald?s-Mas R, Puente XS, Vi?als F, Casanovas O, Graupera M, Hern?ndez-Losa J, Ram?n Y Cajal S, Garc?a-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Mart?n-Mart?n N, Matheu A, Carracedo A, Gonz?lez-Su?rez E, Nanjundan M, Cort?s J, L?zaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017 05 11; 36(19):2737-2749. PMID: 27991928; PMCID: PMC5442428.
      Citations: 16     Fields:    Translation:HumansCells
    79. Corrales L, Matson V, Flood B, Spranger S, Gajewski TF, Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017 Jan; 27(1):96-108. PMID: 27981969; PMCID: PMC5223230.
      Citations: 161     Fields:    Translation:HumansCells
    80. Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD, Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. J Cancer Res Clin Oncol. 2017 Mar; 143(3):439-445. PMID: 27921276; PMCID: PMC5303646.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    81. Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S, Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 01; 123(7):1259-1271. PMID: 27906454; PMCID: PMC5705038.
      Citations: 24     Fields:    Translation:Humans
    82. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M, Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313. PMID: 27846884; PMCID: PMC5111349.
      Citations: 6     Fields:    Translation:HumansAnimals
    83. Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF, Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A. 2016 11 29; 113(48):E7759-E7768. PMID: 27837020; PMCID: PMC5137753.
      Citations: 179     Fields:    Translation:HumansCells
    84. Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL, Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL. Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. Oncoimmunology. 2016; 5(12):e1240857. PMID: 28123876; PMCID: PMC5215363.
      Citations: 35     Fields:    
    85. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ, Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016; 4:50. PMID: 27532025; PMCID: PMC4986340.
      Citations: 196     Fields:    
    86. Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, Alitalo K, Eikesdal HP, Wiig H, Swartz MA, Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, Alitalo K, Eikesdal HP, Wiig H, Swartz MA. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016 09 01; 126(9):3389-402. PMID: 27525437; PMCID: PMC5004967.
      Citations: 97     Fields:    Translation:HumansAnimals
    87. Corrales L, McWhirter SM, Dubensky TW, Gajewski TF, Corrales L, McWhirter SM, Dubensky TW, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016 07 01; 126(7):2404-11. PMID: 27367184; PMCID: PMC4922692.
      Citations: 164     Fields:    Translation:HumansAnimalsCells
    88. Iraolagoitia XL, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nu?ez SY, Secchiari F, Gajewski TF, Zwirner NW, Fuertes MB, Iraolagoitia XL, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nu?ez SY, Secchiari F, Gajewski TF, Zwirner NW, Fuertes MB. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. J Immunol. 2016 08 01; 197(3):953-61. PMID: 27342842.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    89. Luke JJ, Zha Y, Matijevich K, Gajewski TF, Luke JJ, Zha Y, Matijevich K, Gajewski TF. Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. J Immunother Cancer. 2016; 4:35. PMID: 27330808; PMCID: PMC4915048.
      Citations: 10     Fields:    
    90. Lei YM, Chen L, Wang Y, Stefka AT, Molinero LL, Theriault B, Aquino-Michaels K, Sivan AS, Nagler CR, Gajewski TF, Chong AS, Bartman C, Alegre ML, Lei YM, Chen L, Wang Y, Stefka AT, Molinero LL, Theriault B, Aquino-Michaels K, Sivan AS, Nagler CR, Gajewski TF, Chong AS, Bartman C, Alegre ML. The composition of the microbiota modulates allograft rejection. J Clin Invest. 2016 07 01; 126(7):2736-44. PMID: 27322054; PMCID: PMC4922695.
      Citations: 40     Fields:    Translation:AnimalsCells
    91. Gajewski T, Gajewski T. Manipulating the microbiome to improve the efficacy of immunotherapy. Clin Adv Hematol Oncol. 2016 Jun; 14(6):424-6. PMID: 27379811.
      Citations: 4     Fields:    Translation:HumansCells
    92. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF, Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8. PMID: 27197067; PMCID: PMC4943758.
      Citations: 161     Fields:    Translation:HumansCells
    93. Spranger S, Gajewski TF, Kline J, Spranger S, Gajewski TF, Kline J. MYC - a thorn in the side of cancer immunity. Cell Res. 2016 06; 26(6):639-40. PMID: 27113275; PMCID: PMC4897180.
      Citations: 4     Fields:    Translation:Humans
    94. Alegre ML, Gajewski TF, Alegre ML, Gajewski TF. Germ Warfare. Sci Am. 2016 Apr; 314(4):50. PMID: 27082192.
      Citations:    Fields:    Translation:HumansAnimalsCells
    95. Corrales L, Woo SR, Williams JB, McWhirter SM, Dubensky TW, Gajewski TF, Corrales L, Woo SR, Williams JB, McWhirter SM, Dubensky TW, Gajewski TF. Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA. J Immunol. 2016 Apr 01; 196(7):3191-8. PMID: 26927800; PMCID: PMC4800192.
      Citations: 61     Fields:    Translation:AnimalsCells
    96. Evaristo C, Spranger S, Barnes SE, Miller ML, Molinero LL, Locke FL, Gajewski TF, Alegre ML, Evaristo C, Spranger S, Barnes SE, Miller ML, Molinero LL, Locke FL, Gajewski TF, Alegre ML. Cutting Edge: Engineering Active IKK? in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8. PMID: 26903482; PMCID: PMC4799771.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    97. Mikucki ME, Skitzki JJ, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS, Mikucki ME, Skitzki JJ, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS. Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy. Oncoimmunology. 2016 May; 5(5):e1116675. PMID: 27467928; PMCID: PMC4910745.
      Citations: 7     Fields:    
    98. McWhirter E, Quirt I, Gajewski T, Pond G, Wang L, Hui J, Oza A, McWhirter E, Quirt I, Gajewski T, Pond G, Wang L, Hui J, Oza A. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Invest New Drugs. 2016 Apr; 34(2):231-5. PMID: 26841902.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    99. Spranger S, Sivan A, Corrales L, Gajewski TF, Spranger S, Sivan A, Corrales L, Gajewski TF. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy. Adv Immunol. 2016; 130:75-93. PMID: 26923000; PMCID: PMC4864964.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    100. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Liz?e G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P, Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Liz?e G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16. PMID: 26645196; PMCID: PMC4744499.
      Citations: 667     Fields:    Translation:HumansAnimalsCells
    101. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M, Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 2015 Nov 30; 13:374. PMID: 26619946; PMCID: PMC4665874.
      Citations: 6     Fields:    Translation:Humans
    102. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF, Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27; 350(6264):1084-9. PMID: 26541606; PMCID: PMC4873287.
      Citations: 1346     Fields:    Translation:HumansAnimalsCells
    103. Spranger S, Gajewski TF, Spranger S, Gajewski TF. A new paradigm for tumor immune escape: ?-catenin-driven immune exclusion. J Immunother Cancer. 2015; 3:43. PMID: 26380088; PMCID: PMC4570721.
      Citations: 69     Fields:    
    104. Corrales L, Gajewski TF, Corrales L, Gajewski TF. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer. Clin Cancer Res. 2015 Nov 01; 21(21):4774-9. PMID: 26373573; PMCID: PMC4750108.
      Citations: 73     Fields:    Translation:HumansAnimalsCells
    105. Spranger S, Gajewski TF, Spranger S, Gajewski TF. Tumor-intrinsic oncogene pathways mediating immune avoidance. Oncoimmunology. 2016 Mar; 5(3):e1086862. PMID: 27141343; PMCID: PMC4839364.
      Citations: 72     Fields:    
    106. Corrales L, Gajewski TF, Corrales L, Gajewski TF. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine. 2016 Jan; 77:245-7. PMID: 26315534; PMCID: PMC4666728.
      Citations: 17     Fields:    Translation:HumansCells
    107. Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS, Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015 Jun 25; 6:7458. PMID: 26109379; PMCID: PMC4605273.
      Citations: 227     Fields:    Translation:AnimalsCells
    108. Gajewski TF, Gajewski TF. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015 Aug; 42(4):663-71. PMID: 26320069; PMCID: PMC4555998.
      Citations: 231     Fields:    Translation:HumansAnimalsCells
    109. Spranger S, Bao R, Gajewski TF, Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic ?-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 09; 523(7559):231-5. PMID: 25970248.
      Citations: 1208     Fields:    Translation:HumansAnimalsCells
    110. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW, Gajewski TF, Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW, Gajewski TF. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19; 11(7):1018-30. PMID: 25959818; PMCID: PMC4440852.
      Citations: 515     Fields:    Translation:HumansAnimalsCells
    111. Woo SR, Corrales L, Gajewski TF, Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015 Apr; 36(4):250-6. PMID: 25758021; PMCID: PMC4393801.
      Citations: 103     Fields:    Translation:HumansCells
    112. Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS, Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96. PMID: 25695690; PMCID: PMC5013827.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    113. Woo SR, Corrales L, Gajewski TF, Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33:445-74. PMID: 25622193.
      Citations: 226     Fields:    Translation:HumansAnimalsCells
    114. Barnes SE, Wang Y, Chen L, Molinero LL, Gajewski TF, Evaristo C, Alegre ML, Barnes SE, Wang Y, Chen L, Molinero LL, Gajewski TF, Evaristo C, Alegre ML. T cell-NF-?B activation is required for tumor control in vivo. J Immunother Cancer. 2015; 3(1):1. PMID: 25648675; PMCID: PMC4308877.
      Citations: 20     Fields:    
    115. Gajewski TF, Corrales L, Gajewski TF, Corrales L. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015 Apr; 26(2):175-8. PMID: 25630967; PMCID: PMC4387009.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    116. Janardhan SV, Marks R, Gajewski TF, Janardhan SV, Marks R, Gajewski TF. Primary murine CD4+ T cells fail to acquire the ability to produce effector cytokines when active Ras is present during Th1/Th2 differentiation. PLoS One. 2014; 9(11):e112831. PMID: 25397617; PMCID: PMC4232516.
      Citations: 1     Fields:    Translation:AnimalsCells
    117. Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD, Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30. PMID: 25609545; PMCID: PMC4331835.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    118. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR, Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20; 41(5):843-52. PMID: 25517616; PMCID: PMC5155593.
      Citations: 729     Fields:    Translation:AnimalsCells
    119. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF, Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014 Nov 20; 41(5):830-42. PMID: 25517615; PMCID: PMC4384884.
      Citations: 640     Fields:    Translation:AnimalsCells
    120. Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M, Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277. PMID: 25348889; PMCID: PMC4232645.
      Citations: 10     Fields:    Translation:Humans
    121. Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA, Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440. PMID: 25250858; PMCID: PMC4304973.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    122. Spaapen RM, Leung MY, Fuertes MB, Kline JP, Zhang L, Zheng Y, Fu YX, Luo X, Cohen KS, Gajewski TF, Spaapen RM, Leung MY, Fuertes MB, Kline JP, Zhang L, Zheng Y, Fu YX, Luo X, Cohen KS, Gajewski TF. Therapeutic activity of high-dose intratumoral IFN-? requires direct effect on the tumor vasculature. J Immunol. 2014 Oct 15; 193(8):4254-60. PMID: 25217157.
      Citations: 46     Fields:    Translation:AnimalsCells
    123. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA, Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65. PMID: 25037139.
      Citations: 92     Fields:    Translation:HumansCTClinical Trials
    124. Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK, Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Jun 18; 311(23):2397-405. PMID: 24938562; PMCID: PMC4249701.
      Citations: 167     Fields:    Translation:HumansCTClinical Trials
    125. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF, Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014; 2:3. PMID: 24829760; PMCID: PMC4019906.
      Citations: 278     Fields:    
    126. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX, Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX. Targeting the tumor microenvironment with interferon-? bridges innate and adaptive immune responses. Cancer Cell. 2014 Jan 13; 25(1):37-48. PMID: 24434209; PMCID: PMC3927846.
      Citations: 132     Fields:    Translation:AnimalsCells
    127. Gajewski TF, Schreiber H, Fu YX, Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013 Oct; 14(10):1014-22. PMID: 24048123; PMCID: PMC4118725.
      Citations: 1633     Fields:    Translation:HumansAnimalsCells
    128. Spranger S, Gajewski T, Spranger S, Gajewski T. Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer. 2013; 1:16. PMID: 24829752; PMCID: PMC4019905.
      Citations: 34     Fields:    
    129. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF, Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013 Aug 28; 5(200):200ra116. PMID: 23986400; PMCID: PMC4136707.
      Citations: 785     Fields:    Translation:HumansAnimalsCells
    130. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB, Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98. PMID: 23982524.
      Citations: 78     Fields:    Translation:Humans
    131. Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF, Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol. 2013 Aug 15; 191(4):1677-85. PMID: 23851688; PMCID: PMC3759681.
      Citations: 8     Fields:    Translation:AnimalsCells
    132. Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HL, Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer. 2013; 1:8. PMID: 24829746; PMCID: PMC4019890.
      Citations: 20     Fields:    
    133. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE, Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90. PMID: 23775962; PMCID: PMC4878082.
      Citations: 185     Fields:    Translation:HumansCTClinical Trials
    134. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabr? L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M, Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabr? L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137. PMID: 23731854; PMCID: PMC3681569.
      Citations: 12     Fields:    Translation:HumansAnimals
    135. Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, Kline J, Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, Kline J. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013 May; 123(5):1999-2010. PMID: 23619361; PMCID: PMC3635717.
      Citations: 44     Fields:    Translation:AnimalsCells
    136. Gajewski TF, Schumacher T, Gajewski TF, Schumacher T. Cancer immunotherapy. Curr Opin Immunol. 2013 Apr; 25(2):259-60. PMID: 23587868.
      Citations: 9     Fields:    Translation:HumansCells
    137. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S, Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013 Apr; 25(2):268-76. PMID: 23579075.
      Citations: 207     Fields:    Translation:Humans
    138. Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF, Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF. Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol. 2013 Oct; 55(3-4):283-91. PMID: 23548837; PMCID: PMC3646929.
      Citations: 25     Fields:    Translation:AnimalsCells
    139. Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F, Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F, Cancer and Leukemia Group B. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med. 2012 Dec 10; 10:246. PMID: 23228035; PMCID: PMC3543225.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    140. Gangadhar TC, Clark JI, Karrison T, Gajewski TF, Gangadhar TC, Clark JI, Karrison T, Gajewski TF. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73. PMID: 23151808; PMCID: PMC3600382.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    141. Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF, Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med. 2012 Nov 19; 209(12):2157-63. PMID: 23129747; PMCID: PMC3501351.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    142. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF, Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013 Feb; 34(2):67-73. PMID: 23122052; PMCID: PMC3565059.
      Citations: 162     Fields:    Translation:HumansAnimalsCells
    143. Galon J, Pag?s F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA, Galon J, Pag?s F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 03; 10:205. PMID: 23034130; PMCID: PMC3554496.
      Citations: 358     Fields:    Translation:Humans
    144. Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ, Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93. PMID: 22872575; PMCID: PMC4410974.
      Citations: 27     Fields:    Translation:HumansAnimalsCTClinical Trials
    145. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM, Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83. PMID: 22551296; PMCID: PMC3390271.
      Citations: 4     Fields:    Translation:HumansAnimals
    146. Gajewski TF, Fuertes MB, Woo SR, Gajewski TF, Fuertes MB, Woo SR. Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother. 2012 Aug; 61(8):1343-7. PMID: 22722449.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    147. Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I, Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108. PMID: 22640522; PMCID: PMC3404934.
      Citations: 6     Fields:    Translation:HumansAnimals
    148. Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF, Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol. 2012 Mar 15; 188(6):2630-42. PMID: 22312128; PMCID: PMC3294164.
      Citations: 23     Fields:    Translation:AnimalsCells
    149. Shakur SF, Takagi I, Lukas RV, Chmura S, Gajewski TF, Roitberg BZ, Shakur SF, Takagi I, Lukas RV, Chmura S, Gajewski TF, Roitberg BZ. Ocular melanoma metastasis to the cervical spine. J Clin Neurosci. 2012 Apr; 19(4):610-1. PMID: 22245271.
      Citations: 3     Fields:    Translation:Humans
    150. Gajewski TF, Gajewski TF. Cancer immunotherapy. Mol Oncol. 2012 Apr; 6(2):242-50. PMID: 22248437; PMCID: PMC3345039.
      Citations: 38     Fields:    Translation:Humans
    151. Galon J, Pag?s F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA, Galon J, Pag?s F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012 Jan 03; 10:1. PMID: 22214470; PMCID: PMC3269368.
      Citations: 260     Fields:    Translation:Humans
    152. Gajewski T, Gajewski T. Harnessing the immune response. Clin Adv Hematol Oncol. 2012 Jan; 10(1):46-8. PMID: 22398808.
      Citations:    Fields:    Translation:Humans
    153. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, H?kansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML, Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, H?kansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. PMID: 22168571; PMCID: PMC3338100.
      Citations: 71     Fields:    Translation:Humans
    154. Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH, Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH. SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med. 2011 Sep 19; 9:155. PMID: 21929757; PMCID: PMC3189883.
      Citations: 14     Fields:    Translation:Humans
    155. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF, Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 2011 Sep 26; 208(10):2005-16. PMID: 21930765; PMCID: PMC3182064.
      Citations: 543     Fields:    Translation:HumansAnimalsCells
    156. Janardhan SV, Praveen K, Marks R, Gajewski TF, Janardhan SV, Praveen K, Marks R, Gajewski TF. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One. 2011; 6(9):e24931. PMID: 21949793; PMCID: PMC3176298.
      Citations: 13     Fields:    Translation:AnimalsCells
    157. Balwit JM, Kalinski P, Sondak VK, Coulie PG, Jaffee EM, Gajewski TF, Marincola FM, Balwit JM, Kalinski P, Sondak VK, Coulie PG, Jaffee EM, Gajewski TF, Marincola FM. Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med. 2011 May 12; 9:60. PMID: 21569425; PMCID: PMC3115875.
      Citations: 1     Fields:    Translation:Humans
    158. Gajewski TF, Gajewski TF. Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol. 2011 Apr; 38(2):236-42. PMID: 21421113; PMCID: PMC3073764.
      Citations: 7     Fields:    Translation:Humans
    159. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J, Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011 Apr; 23(2):286-92. PMID: 21185705; PMCID: PMC3070788.
      Citations: 71     Fields:    Translation:HumansAnimalsCells
    160. Driessens G, Zheng Y, Locke F, Cannon JL, Gounari F, Gajewski TF, Driessens G, Zheng Y, Locke F, Cannon JL, Gounari F, Gajewski TF. Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-?1 phosphorylation. J Immunol. 2011 Jan 15; 186(2):784-90. PMID: 21149602; PMCID: PMC4888792.
      Citations: 31     Fields:    Translation:AnimalsCells
    161. Kline J, Gajewski TF, Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9. PMID: 21154117.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    162. Gajewski TF, Gajewski TF. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Pigment Cell Melanoma Res. 2010 Oct; 23(5):580-1. PMID: 20609175.
      Citations: 3     Fields:    Translation:Humans
    163. Gajewski TF, Louahed J, Brichard VG, Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010 Jul-Aug; 16(4):399-403. PMID: 20693853.
      Citations: 126     Fields:    Translation:HumansAnimals
    164. Poir? X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM, Poir? X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50. PMID: 20496994.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    165. Driessens G, Zheng Y, Gajewski TF, Driessens G, Zheng Y, Gajewski TF. Beta-catenin does not regulate memory T cell phenotype. Nat Med. 2010 May; 16(5):513-4; author reply 514-5. PMID: 20448567.
      Citations: 24     Fields:    Translation:Animals
    166. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD, O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug; 21(8):1712-1717. PMID: 20147741.
      Citations: 204     Fields:    Translation:HumansCTClinical Trials
    167. Takacs Z, Toups M, Kollewe A, Johnson E, Cuello LG, Driessens G, Biancalana M, Koide A, Ponte CG, Perozo E, Gajewski TF, Suarez-Kurtz G, Koide S, Goldstein SA, Takacs Z, Toups M, Kollewe A, Johnson E, Cuello LG, Driessens G, Biancalana M, Koide A, Ponte CG, Perozo E, Gajewski TF, Suarez-Kurtz G, Koide S, Goldstein SA. A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22211-6. PMID: 20007782; PMCID: PMC2799710.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    168. Schuster K, Gadiot J, Andreesen R, Mackensen A, Gajewski TF, Blank C, Schuster K, Gadiot J, Andreesen R, Mackensen A, Gajewski TF, Blank C. Homeostatic proliferation of na?ve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. Eur J Immunol. 2009 Nov; 39(11):2981-90. PMID: 19658092.
      Citations: 8     Fields:    Translation:AnimalsCells
    169. Locke F, Clark JI, Gajewski TF, Locke F, Clark JI, Gajewski TF. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharmacol. 2010 Feb; 65(3):509-14. PMID: 19597729.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    170. Molinero LL, Yang J, Gajewski T, Abraham C, Farrar MA, Alegre ML, Molinero LL, Yang J, Gajewski T, Abraham C, Farrar MA, Alegre ML. CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells. J Immunol. 2009 Jun 01; 182(11):6736-43. PMID: 19454668; PMCID: PMC2830151.
      Citations: 62     Fields:    Translation:AnimalsCells
    171. Praveen K, Zheng Y, Rivas F, Gajewski TF, Praveen K, Zheng Y, Rivas F, Gajewski TF. Protein kinase Ctheta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol. 2009 May 15; 182(10):6022-30. PMID: 19414753.
      Citations: 2     Fields:    Translation:AnimalsCells
    172. Zhang L, Gajewski TF, Kline J, Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009 Aug 20; 114(8):1545-52. PMID: 19417208; PMCID: PMC2731636.
      Citations: 188     Fields:    Translation:HumansAnimalsCells
    173. Driessens G, Kline J, Gajewski TF, Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009 May; 229(1):126-44. PMID: 19426219; PMCID: PMC3278040.
      Citations: 120     Fields:    Translation:HumansAnimalsCells
    174. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF, Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009 Apr 01; 69(7):3077-85. PMID: 19293190; PMCID: PMC3886718.
      Citations: 539     Fields:    Translation:HumansCells
    175. Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM, Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate. 2009 Feb 01; 69(2):142-8. PMID: 18942640.
      Citations: 4     Fields:    Translation:HumansCells
    176. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A, Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81. PMID: 19139427.
      Citations: 105     Fields:    Translation:HumansCTClinical Trials
    177. Gajewski TF, Chesney J, Curriel TJ, Gajewski TF, Chesney J, Curriel TJ. Emerging strategies in regulatory T-cell immunotherapies. Clin Adv Hematol Oncol. 2009 Jan; 7(1):1-10; quiz 11-2. PMID: 19288606.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    178. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF, Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother. 2009 Aug; 58(8):1351-3. PMID: 19052742.
      Citations: 32     Fields:    Translation:Humans
    179. Cham CM, Driessens G, O'Keefe JP, Gajewski TF, Cham CM, Driessens G, O'Keefe JP, Gajewski TF. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol. 2008 Sep; 38(9):2438-50. PMID: 18792400; PMCID: PMC3008428.
      Citations: 191     Fields:    Translation:AnimalsCells
    180. Lee RT, Fallarino F, Ashikari A, Gajewski TF, Lee RT, Fallarino F, Ashikari A, Gajewski TF. Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Res. 2008 Aug; 18(4):289-94. PMID: 18626315.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    181. O'Day SJ, Ibrahim R, DePril V, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Hoos A, Humphrey R, Wolchock J. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol. 2008 May 20; 26(15_suppl):9021. PMID: 27950718.
      Citations:    
    182. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF, Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008 May 15; 14(10):3156-67. PMID: 18483384.
      Citations: 53     Fields:    Translation:AnimalsCells
    183. Zheng Y, Zha Y, Gajewski TF, Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Rep. 2008 Jan; 9(1):50-5. PMID: 18174897; PMCID: PMC2246614.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    184. Harlin H, Gajewski TF, Harlin H, Gajewski TF. Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr Protoc Cytom. 2008 Jan; Appendix 3:Appendix 3C. PMID: 18770641.
      Citations: 6     Fields:    Translation:Cells
    185. Zha Y, Shah R, Locke F, Wong A, Gajewski TF, Zha Y, Shah R, Locke F, Wong A, Gajewski TF. Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells. J Immunol Methods. 2008 Feb 29; 331(1-2):94-102. PMID: 18177887; PMCID: PMC3278801.
      Citations: 7     Fields:    Translation:AnimalsCells
    186. Zha Y, Gajewski TF, Zha Y, Gajewski TF. An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. Cell Immunol. 2007 Jun; 247(2):95-102. PMID: 17897636; PMCID: PMC3286639.
      Citations: 8     Fields:    Translation:AnimalsCells
    187. Gajewski TF, Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5256-61. PMID: 17875753.
      Citations: 106     Fields:    Translation:HumansCells
    188. Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM, Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother. 2007 Sep; 30(6):577-90. PMID: 17667521.
      Citations: 1     Fields:    Translation:Humans
    189. Gajewski TF, Gajewski TF. The expanding universe of regulatory T cell subsets in cancer. Immunity. 2007 Aug; 27(2):185-7. PMID: 17723212.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    190. Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, Schreiber H, You Z, Kaynor C, Wang X, Fu YX, Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, Schreiber H, You Z, Kaynor C, Wang X, Fu YX. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8. PMID: 17641063; PMCID: PMC2387226.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    191. Marks RE, Ho AW, Robbel C, Kuna T, Berk S, Gajewski TF, Marks RE, Ho AW, Robbel C, Kuna T, Berk S, Gajewski TF. Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007 Sep 15; 110(6):1982-8. PMID: 17545504; PMCID: PMC1976355.
      Citations: 14     Fields:    Translation:HumansCells
    192. Gajewski TF, Gajewski TF. On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol. 2007 Apr 10; 25(11):1305-7. PMID: 17416849.
      Citations: 8     Fields:    Translation:HumansAnimals
    193. Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, Gajewski TF, Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, Gajewski TF. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol. 2006 Nov; 7(11):1166-73. PMID: 17028589.
      Citations: 140     Fields:    Translation:AnimalsCells
    194. Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF, Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006 Oct 01; 177(7):4521-9. PMID: 16982889.
      Citations: 48     Fields:    Translation:AnimalsCells
    195. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H, Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006 Oct; 213:131-45. PMID: 16972901.
      Citations: 208     Fields:    Translation:HumansAnimalsCells
    196. Meng Y, Harlin H, O'Keefe JP, Gajewski TF, Meng Y, Harlin H, O'Keefe JP, Gajewski TF. Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression. J Immunol. 2006 Aug 01; 177(3):1981-7. PMID: 16849512.
      Citations: 19     Fields:    Translation:HumansCells
    197. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A, Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006 Jul 15; 119(2):317-27. PMID: 16482562.
      Citations: 127     Fields:    Translation:HumansCells
    198. Fitch FW, Gajewski TF, Hu-Li J, Fitch FW, Gajewski TF, Hu-Li J. Production of TH1 and TH2 cell lines and clones. Curr Protoc Immunol. 2006 May; Chapter 3:3.13.1-3.13.15. PMID: 18432972.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    199. Gajewski TF, Meng Y, Harlin H, Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother. 2006 May-Jun; 29(3):233-40. PMID: 16699366.
      Citations: 100     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    200. Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L, Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s. PMID: 16609047.
      Citations:    Fields:    Translation:Humans
    201. Gajewski TF, Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2326s-2330s. PMID: 16609053.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    202. Peterson AC, Harlin H, Karrison T, Vogelzang NJ, Knost JA, Kugler JW, Lester E, Vokes E, Gajewski TF, Stadler WM, Peterson AC, Harlin H, Karrison T, Vogelzang NJ, Knost JA, Kugler JW, Lester E, Vokes E, Gajewski TF, Stadler WM, University of Chicago Phase II Consortium. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9. PMID: 16514482.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    203. Velicu S, Han Y, Ulasov I, Brown IE, El Andaloussi A, Gajewski TF, Lesniak MS, Velicu S, Han Y, Ulasov I, Brown IE, El Andaloussi A, Gajewski TF, Lesniak MS. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. J Neuroimmunol. 2006 May; 174(1-2):74-81. PMID: 16504307.
      Citations: 3     Fields:    Translation:AnimalsCells
    204. Tripathi P, Madan R, Chougnet C, Divanovic S, Ma X, Wahl LM, Gajewski T, Karp CL, Hildeman DA, Tripathi P, Madan R, Chougnet C, Divanovic S, Ma X, Wahl LM, Gajewski T, Karp CL, Hildeman DA. An adenoviral vector for probing promoter activity in primary immune cells. J Immunol Methods. 2006 Apr 20; 311(1-2):19-30. PMID: 16563424; PMCID: PMC2964867.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    205. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF, Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97. PMID: 16468035.
      Citations: 49     Fields:    Translation:HumansCells
    206. Harlin H, Gajewski TF, Harlin H, Gajewski TF. Diagnosis and treatment of Mycoplasma-contaminated cell cultures. Curr Protoc Microbiol. 2006 Jan; Appendix 3:Appendix 3B. PMID: 18770568.
      Citations:    Fields:    Translation:Cells
    207. Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG, Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG, Cancer and Leukemia Group B. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101. PMID: 16365605.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    208. O'Keefe JP, Gajewski TF, O'Keefe JP, Gajewski TF. Cutting edge: cytotoxic granule polarization and cytolysis can occur without central supramolecular activation cluster formation in CD8+ effector T cells. J Immunol. 2005 Nov 01; 175(9):5581-5. PMID: 16237042.
      Citations: 22     Fields:    Translation:AnimalsCells
    209. Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE, Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, Vokes EE. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res. 2005 Nov 01; 11(21):7861-5. PMID: 16278409.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    210. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH, Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 01; 104(5):1045-8. PMID: 16007689.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    211. Redman BG, Ernstoff MS, Gajewski TF, Cunningham C, Lawson DH, Gregoire L, Haltom E, Uprichard MJ. Phase 2 trial of talabostat in stage IV melanoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7570. PMID: 27946035.
      Citations:    
    212. Gajewski TF, Peterson AC, Slingluff C, McKee M, Harlin H. Reciprocal expression of indoleamine-2,3-dioxygenase (IDO) and arginase-I in metastatic melanoma tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):7523. PMID: 27946220.
      Citations:    
    213. Cham CM, Gajewski TF, Cham CM, Gajewski TF. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol. 2005 Apr 15; 174(8):4670-7. PMID: 15814691.
      Citations: 174     Fields:    Translation:AnimalsCells
    214. Blank C, Brown I, Kacha AK, Markiewicz MA, Gajewski TF, Blank C, Brown I, Kacha AK, Markiewicz MA, Gajewski TF. ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. J Immunol. 2005 Mar 15; 174(6):3416-20. PMID: 15749875.
      Citations: 13     Fields:    Translation:AnimalsCells
    215. Gajewski TF, Gajewski TF. Lymphoma-infiltrating immune cells. N Engl J Med. 2005 Feb 17; 352(7):724-5; author reply 724-5. PMID: 15719444.
      Citations:    Fields:    Translation:HumansCells
    216. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ, Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60. PMID: 15543195.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    217. Brown IE, Mashayekhi M, Markiewicz M, Alegre ML, Gajewski TF, Brown IE, Mashayekhi M, Markiewicz M, Alegre ML, Gajewski TF. Peripheral survival of na?ve CD8+ T cells. Apoptosis. 2005 Jan; 10(1):5-11. PMID: 15711917.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    218. Cham CM, Gajewski TF, Cham CM, Gajewski TF. Metabolic mechanisms of tumor resistance to T cell effector function. Immunol Res. 2005; 31(2):107-18. PMID: 15778509.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    219. Blank C, Gajewski TF, Mackensen A, Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr; 54(4):307-14. PMID: 15599732.
      Citations: 229     Fields:    Translation:HumansAnimalsCells
    220. Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF, Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22. PMID: 15570084.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    221. Gajewski TF, Gajewski TF. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. Curr Opin Investig Drugs. 2004 Dec; 5(12):1279-83. PMID: 15648949.
      Citations:    Fields:    Translation:HumansAnimals
    222. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM, Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8. PMID: 15221817.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    223. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF, Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol. 2004 Jul; 15(7):1109-14. PMID: 15205206.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    224. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF, Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54. PMID: 15217937.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    225. O'Keefe JP, Blaine K, Alegre ML, Gajewski TF, O'Keefe JP, Blaine K, Alegre ML, Gajewski TF. Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9351-6. PMID: 15192143; PMCID: PMC438980.
      Citations: 19     Fields:    Translation:AnimalsCells
    226. Harlin H, Artz AS, Mahowald M, Rini BI, Zimmerman T, Vogelzang NJ, Gajewski TF, Harlin H, Artz AS, Mahowald M, Rini BI, Zimmerman T, Vogelzang NJ, Gajewski TF. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells. Bone Marrow Transplant. 2004 Mar; 33(5):491-7. PMID: 14716341.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    227. Gajewski TF, Gajewski TF. Update on vaccines for solid tumors. Clin Adv Hematol Oncol. 2004 Mar; 2(3):158-9. PMID: 16166944.
      Citations:    Fields:    Translation:Humans
    228. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF, Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004 Feb 01; 64(3):1140-5. PMID: 14871849.
      Citations: 331     Fields:    Translation:AnimalsCells
    229. Rivas FV, O'Keefe JP, Alegre ML, Gajewski TF, Rivas FV, O'Keefe JP, Alegre ML, Gajewski TF. Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol Cell Biol. 2004 Feb; 24(4):1628-39. PMID: 14749378; PMCID: PMC344175.
      Citations: 31     Fields:    Translation:AnimalsCells
    230. Gajewski TF, Gajewski TF. Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol. 2004 Feb 15; 22(4):580-1. PMID: 14726506.
      Citations: 2     Fields:    Translation:Humans
    231. Zha Yy, Blank C, Gajewski TF, Zha Yy, Blank C, Gajewski TF. Negative regulation of T-cell function by PD-1. Crit Rev Immunol. 2004; 24(4):229-37. PMID: 15588223.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    232. Marks RE, Ho AW, Rivas F, Marshall E, Janardhan S, Gajewski TF, Marks RE, Ho AW, Rivas F, Marshall E, Janardhan S, Gajewski TF. Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun. 2003 Dec 19; 312(3):691-6. PMID: 14680820.
      Citations: 10     Fields:    Translation:AnimalsCells
    233. Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF, Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol. 2003 Nov 01; 171(9):4574-81. PMID: 14568931.
      Citations: 41     Fields:    Translation:AnimalsCells
    234. Markiewicz MA, Brown I, Gajewski TF, Markiewicz MA, Brown I, Gajewski TF. Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xL. Eur J Immunol. 2003 Oct; 33(10):2917-26. PMID: 14515276.
      Citations: 12     Fields:    Translation:AnimalsCells
    235. Peterson AC, Marks RE, Fields PE, Imamoto A, Gajewski TF, Peterson AC, Marks RE, Fields PE, Imamoto A, Gajewski TF. T cell development and function in CrkL-deficient mice. Eur J Immunol. 2003 Oct; 33(10):2687-95. PMID: 14515252.
      Citations: 5     Fields:    Translation:AnimalsCells
    236. Tschoep K, Manning TC, Harlin H, George C, Johnson M, Gajewski TF, Tschoep K, Manning TC, Harlin H, George C, Johnson M, Gajewski TF. Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. J Leukoc Biol. 2003 Jul; 74(1):69-80. PMID: 12832444.
      Citations: 6     Fields:    Translation:HumansCells
    237. Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, Gajewski TF, Fu YX, Zheng P, Liu Y, Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, Gajewski TF, Fu YX, Zheng P, Liu Y. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003 Jun 16; 197(12):1721-30. PMID: 12810690; PMCID: PMC2193953.
      Citations: 48     Fields:    Translation:AnimalsCells
    238. Peterson AC, Harlin H, Gajewski TF, Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003 Jun 15; 21(12):2342-8. PMID: 12805336.
      Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
    239. Cham CM, Xu H, O'Keefe JP, Rivas FV, Zagouras P, Gajewski TF, Cham CM, Xu H, O'Keefe JP, Rivas FV, Zagouras P, Gajewski TF. Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J Biol Chem. 2003 May 09; 278(19):17044-52. PMID: 12582156.
      Citations: 11     Fields:    Translation:AnimalsCells
    240. Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE, Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):191-6. PMID: 12581572.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    241. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H, Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47. PMID: 12479820.
      Citations: 90     Fields:    Translation:AnimalsCells
    242. Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML, Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA, Alegre ML. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002 Jul 15; 169(2):633-7. PMID: 12097362.
      Citations: 8     Fields:    Translation:AnimalsCells
    243. Rini BI, Paintal A, Vogelzang NJ, Gajewski TF, Stadler WM, Rini BI, Paintal A, Vogelzang NJ, Gajewski TF, Stadler WM. Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity. J Immunother. 2002 May-Jun; 25(3):269-77. PMID: 12000869.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    244. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ, Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002 Apr 15; 20(8):2017-24. PMID: 11956260.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    245. Gajewski TF, Gajewski TF. Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemother Biol Response Modif. 2002; 20:343-9. PMID: 12703213.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    246. Rivas FV, O'Herrin S, Gajewski TF, Rivas FV, O'Herrin S, Gajewski TF. CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8. PMID: 11544297.
      Citations: 10     Fields:    Translation:AnimalsCells
    247. O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA, O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001 Sep 01; 167(5):2555-60. PMID: 11509595.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    248. Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF, Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol. 2001 May; 13(5):625-32. PMID: 11312250.
      Citations: 14     Fields:    Translation:AnimalsCells
    249. Gajewski TF, Markiewicz MA, Uyttenhove C, Gajewski TF, Markiewicz MA, Uyttenhove C. The p815 mastocytoma tumor model. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.4. PMID: 18432777.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    250. Fitch FW, Gajewski TF, Yokoyama WM, Fitch FW, Gajewski TF, Yokoyama WM. Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr Protoc Immunol. 2001 May; Appendix 3:Appendix 3E. PMID: 18432657.
      Citations:    Fields:    Translation:Cells
    251. Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ, Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001 Apr; 165(4):1208-9. PMID: 11257677.
      Citations: 1     Fields:    Translation:Humans
    252. Gajewski TF, Fallarino F, Fields PE, Rivas F, Alegre ML, Gajewski TF, Fallarino F, Fields PE, Rivas F, Alegre ML. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol. 2001 Mar 15; 166(6):3900-7. PMID: 11238634.
      Citations: 14     Fields:    Translation:AnimalsCellsPHPublic Health
    253. Gajewski TF, Fallarino F, Ashikari A, Sherman M, Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res. 2001 Mar; 7(3 Suppl):895s-901s. PMID: 11300489.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    254. Alegre M, Fallarino F, Zhou P, Frauwirth K, Thistlethwaite J, Newell K, Gajewski T, Bluestone J, Alegre M, Fallarino F, Zhou P, Frauwirth K, Thistlethwaite J, Newell K, Gajewski T, Bluestone J. Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11. PMID: 11266782.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    255. Wan YY, Leon RP, Marks R, Cham CM, Schaack J, Gajewski TF, DeGregori J, Wan YY, Leon RP, Marks R, Cham CM, Schaack J, Gajewski TF, DeGregori J. Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells. Proc Natl Acad Sci U S A. 2000 Dec 05; 97(25):13784-9. PMID: 11095726; PMCID: PMC17653.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    256. Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF, Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000 Dec 01; 165(11):6024-8. PMID: 11086033.
      Citations: 26     Fields:    Translation:AnimalsCells
    257. Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, Fallarino F, Collins M, Segal DM, Gajewski TF, Kranz DM, Bluestone JA, Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, Fallarino F, Collins M, Segal DM, Gajewski TF, Kranz DM, Bluestone JA. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol. 2000 May 01; 164(9):4433-42. PMID: 10779742.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    258. Gajewski TF, Gajewski TF. Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. Clin Diagn Lab Immunol. 2000 Mar; 7(2):141-4. PMID: 10702484; PMCID: PMC95840.
      Citations: 6     Fields:    Translation:HumansCells
    259. Fields PE, Gajewski TF, Fields PE, Gajewski TF. Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation. Methods Mol Biol. 2000; 134:307-17. PMID: 10730269.
      Citations: 5     Fields:    Translation:HumansCells
    260. Fallarino F, Gajewski TF, Fallarino F, Gajewski TF. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999 Oct 15; 163(8):4109-13. PMID: 10510345.
      Citations: 23     Fields:    Translation:AnimalsCellsPHPublic Health
    261. Rini BI, Gajewski TF, Rini BI, Gajewski TF. Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide. Ann Oncol. 1999 Aug; 10(8):973-9. PMID: 10509161.
      Citations: 3     Fields:    Translation:Humans
    262. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A, Leo O, Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A, Leo O. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer. 1999 May 05; 81(3):428-37. PMID: 10209958.
      Citations: 7     Fields:    Translation:AnimalsCells
    263. Fallarino F, Uyttenhove C, Boon T, Gajewski TF, Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer. 1999 Jan 18; 80(2):324-33. PMID: 9935218.
      Citations: 5     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    264. Markiewicz MA, Gajewski TF, Markiewicz MA, Gajewski TF. The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog. 1999; 10(3):247-60. PMID: 10468184.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    265. Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K, Lee K, Wolf S, Gajewski TF, Fitch FW, Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K, Lee K, Wolf S, Gajewski TF, Fitch FW. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol. 1998 Nov 15; 161(10):5268-75. PMID: 9820499.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    266. Alegre ML, Shiels H, Thompson CB, Gajewski TF, Alegre ML, Shiels H, Thompson CB, Gajewski TF. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol. 1998 Oct 01; 161(7):3347-56. PMID: 9759851.
      Citations: 49     Fields:    Translation:AnimalsCells
    267. Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang CR, Reiner SL, Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang CR, Reiner SL. Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998 Aug; 9(2):229-37. PMID: 9729043.
      Citations: 252     Fields:    Translation:AnimalsCells
    268. Fallarino F, Fields PE, Gajewski TF, Fallarino F, Fields PE, Gajewski TF. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med. 1998 Jul 06; 188(1):205-10. PMID: 9653097; PMCID: PMC2525552.
      Citations: 48     Fields:    Translation:AnimalsCells
    269. Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM, Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol. 1997 Nov 15; 159(10):4665-75. PMID: 9366389.
      Citations: 12     Fields:    Translation:AnimalsCells
    270. Fallarino F, Ashikari A, Boon T, Gajewski TF, Fallarino F, Ashikari A, Boon T, Gajewski TF. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol. 1997 Sep; 9(9):1259-69. PMID: 9310829.
      Citations: 7     Fields:    Translation:AnimalsCells
    271. Uyttenhove C, Godfraind C, Leth? B, Amar-Costesec A, Renauld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Van den Eynde BJ, Uyttenhove C, Godfraind C, Leth? B, Amar-Costesec A, Renauld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Van den Eynde BJ. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 1997 Jan 27; 70(3):349-56. PMID: 9033639.
      Citations: 20     Fields:    Translation:AnimalsCells
    272. Gajewski TF, Thompson CB, Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell. 1996 Nov 15; 87(4):589-92. PMID: 8929527.
      Citations: 48     Fields:    Translation:Cells
    273. Fields P, Fitch FW, Gajewski TF, Fields P, Fitch FW, Gajewski TF. Control of T lymphocyte signal transduction through clonal anergy. J Mol Med (Berl). 1996 Nov; 74(11):673-83. PMID: 8956153.
      Citations: 8     Fields:    Translation:Cells
    274. Warnier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T, Warnier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int J Cancer. 1996 Jul 17; 67(2):303-10. PMID: 8760603.
      Citations: 4     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    275. Gajewski TF, Fallarino F, Uyttenhove C, Boon T, Gajewski TF, Fallarino F, Uyttenhove C, Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol. 1996 Apr 15; 156(8):2909-17. PMID: 8609411.
      Citations: 20     Fields:    Translation:AnimalsCells
    276. Fields PE, Gajewski TF, Fitch FW, Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4+ T cells. Science. 1996 Mar 01; 271(5253):1276-8. PMID: 8638108.
      Citations: 104     Fields:    Translation:AnimalsCells
    277. Fallarino F, Uyttenhove C, Boon T, Gajewski TF, Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol. 1996 Feb 01; 156(3):1095-100. PMID: 8557984.
      Citations: 17     Fields:    Translation:AnimalsCells
    278. Gajewski TF, Gajewski TF. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996 Jan 15; 156(2):465-72. PMID: 8543795.
      Citations: 16     Fields:    Translation:AnimalsCells
    279. Gajewski TF, Fallarino F, Gajewski TF, Fallarino F. Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol. 1995 Aug; 2(4):211-25. PMID: 9358613.
      Citations: 2     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    280. Boon T, Gajewski TF, Coulie PG, Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today. 1995 Jul; 16(7):334-6. PMID: 7576068.
      Citations: 21     Fields:    Translation:HumansAnimalsPHPublic Health
    281. Gajewski TF, Fields P, Fitch FW, Gajewski TF, Fields P, Fitch FW. Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur J Immunol. 1995 Jul; 25(7):1836-42. PMID: 7621861.
      Citations: 15     Fields:    Translation:AnimalsCells
    282. Gajewski TF, Renauld JC, Van Pel A, Boon T, Gajewski TF, Renauld JC, Van Pel A, Boon T. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol. 1995 Jun 01; 154(11):5637-48. PMID: 7538528.
      Citations: 16     Fields:    Translation:AnimalsCells
    283. Lancki DW, Qian D, Fields P, Gajewski T, Fitch FW, Lancki DW, Qian D, Fields P, Gajewski T, Fitch FW. Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1. J Immunol. 1995 May 01; 154(9):4363-70. PMID: 7722293.
      Citations: 5     Fields:    Translation:AnimalsCells
    284. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Bo?l P, De Smet C, Traversari C, Townsend A, Boon T, van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Bo?l P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec; 24(12):3038-43. PMID: 7805731.
      Citations: 74     Fields:    Translation:HumansCells
    285. Gajewski TF, Lancki DW, Stack R, Fitch FW, Gajewski TF, Lancki DW, Stack R, Fitch FW. "Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J Exp Med. 1994 Feb 01; 179(2):481-91. PMID: 8294862; PMCID: PMC2191376.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    286. Gajewski TF, Qian D, Fields P, Fitch FW, Gajewski TF, Qian D, Fields P, Fitch FW. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci U S A. 1994 Jan 04; 91(1):38-42. PMID: 7506419; PMCID: PMC42881.
      Citations: 35     Fields:    Translation:AnimalsCells
    287. Fabry Z, Sandor M, Gajewski TF, Herlein JA, Waldschmidt MM, Lynch RG, Hart MN, Fabry Z, Sandor M, Gajewski TF, Herlein JA, Waldschmidt MM, Lynch RG, Hart MN. Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes. J Immunol. 1993 Jul 01; 151(1):38-47. PMID: 8100844.
      Citations: 18     Fields:    Translation:AnimalsCells
    288. Fitch FW, McKisic MD, Lancki DW, Gajewski TF, Fitch FW, McKisic MD, Lancki DW, Gajewski TF. Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol. 1993; 11:29-48. PMID: 8476563.
      Citations: 56     Fields:    Translation:AnimalsCells
    289. Magilavy DB, Foys KM, Gajewski TF, Magilavy DB, Foys KM, Gajewski TF. Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones. Eur J Immunol. 1992 Sep; 22(9):2359-65. PMID: 1387611.
      Citations: 6     Fields:    Translation:AnimalsCells
    290. Barrett TA, Gajewski TF, Danielpour D, Chang EB, Beagley KW, Bluestone JA, Barrett TA, Gajewski TF, Danielpour D, Chang EB, Beagley KW, Bluestone JA. Differential function of intestinal intraepithelial lymphocyte subsets. J Immunol. 1992 Aug 15; 149(4):1124-30. PMID: 1380032.
      Citations: 45     Fields:    Translation:AnimalsCells
    291. Gold MR, Gajewski TF, DeFranco AL, Gold MR, Gajewski TF, DeFranco AL. Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor beta 1 and dexamethasone. Int Immunol. 1991 Nov; 3(11):1091-8. PMID: 1760404.
      Citations:    Fields:    Translation:AnimalsCells
    292. Gajewski TF, Pinnas M, Wong T, Fitch FW, Gajewski TF, Pinnas M, Wong T, Fitch FW. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol. 1991 Mar 15; 146(6):1750-8. PMID: 1826010.
      Citations: 87     Fields:    Translation:AnimalsCells
    293. Gajewski TF, Fitch FW, Gajewski TF, Fitch FW. Differential activation of murine TH1 and TH2 clones. Res Immunol. 1991 Jan; 142(1):19-23. PMID: 1829255.
      Citations: 7     Fields:    Translation:AnimalsCells
    294. Sandor M, Gajewski T, Thorson J, Kemp JD, Fitch FW, Lynch RG, Sandor M, Gajewski T, Thorson J, Kemp JD, Fitch FW, Lynch RG. CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset. J Exp Med. 1990 Jun 01; 171(6):2171-6. PMID: 1972182; PMCID: PMC2187953.
      Citations: 9     Fields:    Translation:AnimalsCells
    295. Gajewski TF, Schell SR, Fitch FW, Gajewski TF, Schell SR, Fitch FW. Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones. J Immunol. 1990 Jun 01; 144(11):4110-20. PMID: 2140386.
      Citations: 52     Fields:    Translation:AnimalsCells
    296. Gajewski TF, Fitch FW, Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. J Immunol. 1990 Jan 15; 144(2):548-56. PMID: 2104898.
      Citations: 12     Fields:    Translation:AnimalsCells
    297. Gajewski TF, Schell SR, Nau G, Fitch FW, Gajewski TF, Schell SR, Nau G, Fitch FW. Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev. 1989 Oct; 111:79-110. PMID: 2534116.
      Citations: 55     Fields:    Translation:HumansCells
    298. Magilavy DB, Fitch FW, Gajewski TF, Magilavy DB, Fitch FW, Gajewski TF. Murine hepatic accessory cells support the proliferation of Th1 but not Th2 helper T lymphocyte clones. J Exp Med. 1989 Sep 01; 170(3):985-90. PMID: 2527946; PMCID: PMC2189453.
      Citations: 15     Fields:    Translation:AnimalsCells
    299. Gajewski TF, Joyce J, Fitch FW, Gajewski TF, Joyce J, Fitch FW. Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol. 1989 Jul 01; 143(1):15-22. PMID: 2525146.
      Citations: 96     Fields:    Translation:AnimalsCells
    300. Cron RQ, Gajewski TF, Sharrow SO, Fitch FW, Matis LA, Bluestone JA, Cron RQ, Gajewski TF, Sharrow SO, Fitch FW, Matis LA, Bluestone JA. Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells. J Immunol. 1989 Jun 01; 142(11):3754-62. PMID: 2523934.
      Citations: 28     Fields:    Translation:AnimalsCells
    301. Gajewski TF, Goldwasser E, Fitch FW, Gajewski TF, Goldwasser E, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor. J Immunol. 1988 Oct 15; 141(8):2635-42. PMID: 2971726.
      Citations: 19     Fields:    Translation:AnimalsCells
    302. Gajewski TF, Fitch FW, Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988 Jun 15; 140(12):4245-52. PMID: 2967332.
      Citations: 210     Fields:    Translation:AnimalsCells
    303. Fitch F, Gajewski T, Nau G, Schell S, Otten G, Fitch F, Gajewski T, Nau G, Schell S, Otten G. Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors. Princess Takamatsu Symp. 1988; 19:15-27. PMID: 2978617.
      Citations:    Fields:    Translation:HumansAnimalsCells
    304. Dunn DE, Herold KC, Otten GR, Lancki DW, Gajewski T, Vogel SN, Fitch FW, Dunn DE, Herold KC, Otten GR, Lancki DW, Gajewski T, Vogel SN, Fitch FW. Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways. J Immunol. 1987 Dec 15; 139(12):3942-8. PMID: 3121725.
      Citations: 4     Fields:    Translation:AnimalsCells
    305. Ma DI, Wilde DB, Gajewski T, Dunn DE, Fitch FW, Ma DI, Wilde DB, Gajewski T, Dunn DE, Fitch FW. Evidence implicating I region-restricted antigen presentation in alloantigen and nominal antigen recognition by a dual-reactive helper T lymphocyte clone. J Immunol. 1984 Sep; 133(3):1101-10. PMID: 6235280.
      Citations: 1     Fields:    Translation:AnimalsCells
    306. Broda R, Gajewski T, Krzok J, Broda R, Gajewski T, Krzok J. [Case of foreign body in the brain]. Wiad Lek. 1979 Dec 15; 32(24):1777-9. PMID: 545900.
      Citations:    Fields:    Translation:Humans
    307. Rogalski E, Wyrwa E, Gajewski T, Rogalski E, Wyrwa E, Gajewski T. [Use of valvular drainage of the pleural cavity in the treatment of spontaneous pneumothorax]. Pol Przegl Chir. 1972 Aug; 44(8):1373-7. PMID: 5070946.
      Citations:    Fields:    Translation:Humans
    308. Gajewski T, Tylicki C, Gajewski T, Tylicki C. [2- and multistage surgical procedures on the intestines]. Pol Przegl Chir. 1967 Dec; 39(12):1277-80. PMID: 5594258.
      Citations:    Fields:    Translation:Humans
    309. GAJEWSKI T, GAJEWSKI T. [Osteoid osteoma]. Pol Przegl Chir. 1962 Jul; 34:721-3. PMID: 13946179.
      Citations:    Fields:    Translation:Humans
    310. GAJEWSKI T, JEZEWSKA D, GAJEWSKI T, JEZEWSKA D. [A case of effusion of chyle into the pleural and peritoneal cavity]. Pediatr Pol. 1962 Feb; 37:183-6. PMID: 13896281.
      Citations:    Fields:    Translation:Humans
    311. GAJEWSKI T, GOLAB W, GAJEWSKI T, GOLAB W. [Perthes' syndrome after crushing of the thorax]. Pol Tyg Lek. 1961 Jan 16; 16:94-6. PMID: 13702984.
      Citations:    Fields:    Translation:Humans
    312. GAJEWSKI T, KUSMIERSKI S, GAJEWSKI T, KUSMIERSKI S. [Parotitis as a postoperative complication]. Pol Tyg Lek. 1959 Nov 30; 14:2117-9. PMID: 13825979.
      Citations:    Fields:    
    313. GAJEWSKI T, GAJEWSKI T. [Indications concerning the management of patients with artificial anus]. Pol Tyg Lek. 1959 Jun 29; 14:1212-4. PMID: 13825980.
      Citations:    Fields:    Translation:Humans
    314. GAJEWSKI T, GAJEWSKI T. [Surgical treatment of a case of giant hypertrophy of the mandible]. Pol Tyg Lek (Wars). 1956 Apr 23; 11(17):751-4. PMID: 13349730.
      Citations:    
    Gajewski's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (847)
    Explore
    _
    Co-Authors (96)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _